Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Authors:
Al B. Benson IIIRobert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Al B. Benson III in
Current site
Google Scholar
PubMed
Close
 MD
,
Alan P. VenookUCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Alan P. Venook in
Current site
Google Scholar
PubMed
Close
 MD
,
Mahmoud M. Al-HawaryUniversity of Michigan Rogel Cancer Center;

Search for other papers by Mahmoud M. Al-Hawary in
Current site
Google Scholar
PubMed
Close
 MD
,
Nilofer AzadThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Nilofer Azad in
Current site
Google Scholar
PubMed
Close
 MD
,
Yi-Jen ChenCity of Hope National Medical Center;

Search for other papers by Yi-Jen Chen in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Kristen K. CiomborVanderbilt-Ingram Cancer Center;

Search for other papers by Kristen K. Ciombor in
Current site
Google Scholar
PubMed
Close
 MD
,
Stacey CohenFred Hutchinson Cancer Center;

Search for other papers by Stacey Cohen in
Current site
Google Scholar
PubMed
Close
 MD
,
Harry S. CooperFox Chase Cancer Center;

Search for other papers by Harry S. Cooper in
Current site
Google Scholar
PubMed
Close
 MD
,
Dustin DemingUniversity of Wisconsin Carbone Cancer Center;

Search for other papers by Dustin Deming in
Current site
Google Scholar
PubMed
Close
 MD
,
Ignacio Garrido-LagunaHuntsman Cancer Institute at the University of Utah;

Search for other papers by Ignacio Garrido-Laguna in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Jean L. GremFred & Pamela Buffett Cancer Center;

Search for other papers by Jean L. Grem in
Current site
Google Scholar
PubMed
Close
 MD
,
Andrew GunnO’Neal Comprehensive Cancer Center at UAB;

Search for other papers by Andrew Gunn in
Current site
Google Scholar
PubMed
Close
 MD
,
J. Randolph HechtUCLA Jonsson Comprehensive Cancer Center;

Search for other papers by J. Randolph Hecht in
Current site
Google Scholar
PubMed
Close
 MD
,
Sarah HoffeMoffitt Cancer Center;

Search for other papers by Sarah Hoffe in
Current site
Google Scholar
PubMed
Close
 MD
,
Joleen HubbardMayo Clinic Cancer Center;

Search for other papers by Joleen Hubbard in
Current site
Google Scholar
PubMed
Close
 MD
,
Steven HuntSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Steven Hunt in
Current site
Google Scholar
PubMed
Close
 MD
,
William JeckDuke Cancer Institute;

Search for other papers by William Jeck in
Current site
Google Scholar
PubMed
Close
 MD
,
Kimberly L. JohungYale Cancer Center/Smilow Cancer Hospital;

Search for other papers by Kimberly L. Johung in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Natalie KirilcukStanford Cancer Institute;

Search for other papers by Natalie Kirilcuk in
Current site
Google Scholar
PubMed
Close
 MD
,
Smitha KrishnamurthiCase Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Smitha Krishnamurthi in
Current site
Google Scholar
PubMed
Close
 MD
,
Jennifer K. MarattIndiana University Melvin and Bren Simon Comprehensive Cancer Center;

Search for other papers by Jennifer K. Maratt in
Current site
Google Scholar
PubMed
Close
 MD
,
Wells A. MessersmithUniversity of Colorado Cancer Center;

Search for other papers by Wells A. Messersmith in
Current site
Google Scholar
PubMed
Close
 MD
,
Jeffrey MeyerhardtDana-Farber Brigham and Women’s Cancer Center;

Search for other papers by Jeffrey Meyerhardt in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Eric D. MillerThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Eric D. Miller in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Mary F. MulcahyRobert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Mary F. Mulcahy in
Current site
Google Scholar
PubMed
Close
 MD
,
Steven NurkinRoswell Park Comprehensive Cancer Center;

Search for other papers by Steven Nurkin in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Michael J. OvermanThe University of Texas MD Anderson Cancer Center;

Search for other papers by Michael J. Overman in
Current site
Google Scholar
PubMed
Close
 MD
,
Aparna ParikhMassachusetts General Hospital Cancer Center;

Search for other papers by Aparna Parikh in
Current site
Google Scholar
PubMed
Close
 MD
,
Hitendra PatelUC San Diego Moores Cancer Center;

Search for other papers by Hitendra Patel in
Current site
Google Scholar
PubMed
Close
 MD
,
Katrina PedersenSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Katrina Pedersen in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Leonard SaltzMemorial Sloan Kettering Cancer Center;

Search for other papers by Leonard Saltz in
Current site
Google Scholar
PubMed
Close
 MD
,
Charles SchneiderAbramson Cancer Center at the University of Pennsylvania;

Search for other papers by Charles Schneider in
Current site
Google Scholar
PubMed
Close
 MD
,
David ShibataThe University of Tennessee Health Science Center;

Search for other papers by David Shibata in
Current site
Google Scholar
PubMed
Close
 MD
,
John M. SkibberThe University of Texas MD Anderson Cancer Center;

Search for other papers by John M. Skibber in
Current site
Google Scholar
PubMed
Close
 MD
,
Constantinos T. SofocleousMemorial Sloan Kettering Cancer Center;

Search for other papers by Constantinos T. Sofocleous in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Eden Stotsky-HimelfarbThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Eden Stotsky-Himelfarb in
Current site
Google Scholar
PubMed
Close
 BSN, RN
,
Anna TavakkoliUT Southwestern Simmons Comprehensive Cancer Center; and

Search for other papers by Anna Tavakkoli in
Current site
Google Scholar
PubMed
Close
 MD, MSc
,
Christopher G. WillettDuke Cancer Institute;

Search for other papers by Christopher G. Willett in
Current site
Google Scholar
PubMed
Close
 MD
,
Kristina GregoryNational Comprehensive Cancer Network.

Search for other papers by Kristina Gregory in
Current site
Google Scholar
PubMed
Close
 RN, MSN
, and
Lisa GurskiNational Comprehensive Cancer Network.

Search for other papers by Lisa Gurski in
Current site
Google Scholar
PubMed
Close
 PhD

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a “watch-and-wait” nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org, covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.

Individual Disclosures for the NCCN Rectal Cancer Panel
Individual Disclosures for the NCCN Rectal Cancer Panel

  • Collapse
  • Expand
  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:733.

  • 2.

    Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70:145164.

  • 4.

    Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015;150:1722.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Weinberg BA, Marshall JL, Salem ME. The growing challenge of young adults with colorectal cancer. Oncology (Williston Park) 2017;31:381389.

    • Search Google Scholar
    • Export Citation
  • 6.

    Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, et al., eds. WHO Classification of Tumours of the Digestive System. 4th ed. IARC, Lyon. 2010.

    • Search Google Scholar
    • Export Citation
  • 7.

    Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006;130:318324.

  • 8.

    Cooper HS, Deppisch LM, Gourley WK, et al. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology 1995;108:16571665.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Yoshii S, Nojima M, Nosho K, et al. Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors. Clin Gastroenterol Hepatol 2014;12:292302.e3.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Seitz U, Bohnacker S, Seewald S, et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004;47:17891796; discussion 1796–1797.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385394.

  • 12.

    Volk EE, Goldblum JR, Petras RE, et al. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995;109:18011807.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Choi DH, Sohn DK, Chang HJ, et al. Indications for subsequent surgery after endoscopic resection of submucosally invasive colorectal carcinomas: a prospective cohort study. Dis Colon Rectum 2009;52:438445.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Choi JY, Jung SA, Shim KN, et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma. J Korean Med Sci 2015;30:398406.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Park KJ, Choi HJ, Roh MS, et al. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005;48:15971602.

  • 16.

    Rogers AC, Winter DC, Heeney A, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer 2016;115:831840.

  • 17.

    Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:10141020.

  • 18.

    Rajput A, Bullard Dunn K. Surgical management of rectal cancer. Semin Oncol 2007;34:241249.

  • 19.

    Weiser MR, Landmann RG, Wong WD, et al. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum 2005;48:11691175.

  • 20.

    Wiig JN, Larsen SG, Giercksky KE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res 2005;165:136147.

  • 21.

    Morino M, Risio M, Bach S, et al. Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg Endosc 2015;29:755773.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin North Am 2002;31:827839.

  • 23.

    Zhang G, Cai YZ, Xu GH. Diagnostic accuracy of MRI for assessment of T category and circumferential resection margin involvement in patients with rectal cancer: a meta-analysis. Dis Colon Rectum 2016;59:789799.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Balyasnikova S, Brown G. Optimal imaging strategies for rectal cancer staging and ongoing management. Curr Treat Options Oncol 2016;17:32.

  • 25.

    Battersby NJ, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II Study. Ann Surg 2016;263:751760.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Beets-Tan RG, Beets GL. Rectal cancer: review with emphasis on MR imaging. Radiology 2004;232:335346.

  • 27.

    Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: the current role of MRI. Eur Radiol 2007;17:379389.

  • 28.

    Lahaye MJ, Engelen SM, Nelemans PJ, et al. Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 2005;26:259268.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Xie H, Zhou X, Zhuo Z, et al. Effectiveness of MRI for the assessment of mesorectal fascia involvement in patients with rectal cancer: a systematic review and meta-analysis. Dig Surg 2014;31:123134.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006;333:779.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Taylor FG, Quirke P, Heald RJ, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014;32:3443.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Faletti R, Gatti M, Arezzo A, et al. Preoperative staging of rectal cancer using magnetic resonance imaging: comparison with pathological staging. Minerva Chir 2018;73:1319.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Beets-Tan RG, Lambregts DMJ, Maas M, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 2018;28:14651475.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Bipat S, Glas AS, Slors FJ, et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology 2004;232:773783.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Wolberink SV, Beets-Tan RG, de Haas-Kock DF, et al. Conventional CT for the prediction of an involved circumferential resection margin in primary rectal cancer. Dig Dis 2007;25:8085.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Ashraf S, Hompes R, Slater A, et al. A critical appraisal of endorectal ultrasound and transanal endoscopic microsurgery and decision-making in early rectal cancer. Colorectal Dis 2012;14:821826.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Choi DJ, Kwak JM, Kim J, et al. Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer: its role in staging and impact on treatment strategy. J Surg Oncol 2010;102:588592.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Grossmann I, Avenarius JK, Mastboom WJ, et al. Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure. Ann Surg Oncol 2010;17:20452050.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Qiu M, Hu J, Yang D, et al. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget 2015;6:3865838666.

  • 40.

    Hayashi M, Inoue Y, Komeda K, et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 2010;10:27.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Muratore A, Zorzi D, Bouzari H, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766770.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    de Jong EA, ten Berge JC, Dwarkasing RS, et al. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: a metaanalysis. Surgery 2016;159:688699.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Dickman R, Kundel Y, Levy-Drummer R, et al. Restaging locally advanced rectal cancer by different imaging modalities after preoperative chemoradiation: a comparative study. Radiat Oncol 2013;8:278.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Guillem JG, Ruby JA, Leibold T, et al. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg 2013;258:289295.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Hanly AM, Ryan EM, Rogers AC, et al. Multicenter evaluation of rectal cancer reimaging post neoadjuvant (MERRION) therapy. Ann Surg 2014;259:723727.

  • 46.

    Kuo LJ, Chiou JF, Tai CJ, et al. Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? Int J Colorectal Dis 2012;27:613621.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Memon S, Lynch AC, Bressel M, et al. Systematic review and meta- analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Dis 2015;17:748761.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Ryan JE, Warrier SK, Lynch AC, et al. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis 2015;17:849861.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    van der Paardt MP, Zagers MB, Beets-Tan RG, et al. Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 2013;269:101112.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Zhao RS, Wang H, Zhou ZY, et al. Restaging of locally advanced rectal cancer with magnetic resonance imaging and endoluminal ultrasound after preoperative chemoradiotherapy: a systemic review and meta-analysis. Dis Colon Rectum 2014;57:388395.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Park HJ, Jang JK, Park SH, et al. Restaging abdominopelvic computed tomography before surgery after preoperative chemoradiotherapy in patients with locally advanced rectal cancer. JAMA Oncol 2018;4:259262.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Hötker AM, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI of rectal cancer in the assessment of response to therapy: a systematic review. Dis Colon Rectum 2014;57:790799.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Joye I, Deroose CM, Vandecaveye V, et al. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol 2014;113:158165.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Lambregts DM, Rao SX, Sassen S, et al. MRI and diffusion-weighted MRI volumetry for identification of complete tumor responders after preoperative chemoradiotherapy in patients with rectal cancer: a bi-institutional validation study. Ann Surg 2015;262:10341039.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Memon S, Lynch AC, Akhurst T, et al. Systematic review of FDG-PET prediction of complete pathological response and survival in rectal cancer. Ann Surg Oncol 2014;21:35983607.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Guillem JG, Cohen AM. Current issues in colorectal cancer surgery. Semin Oncol 1999;26:505513.

  • 57.

    Lindsetmo RO, Joh YG, Delaney CP. Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know. World J Gastroenterol 2008;14:32813289.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Willett CG, Compton CC, Shellito PC, et al. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer 1994;73:27162720.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 59.

    Clancy C, Burke JP, Albert MR, et al. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. Dis Colon Rectum 2015;58:254261.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Chen Y, Guo R, Xie J, et al. Laparoscopy combined with transanal endoscopic microsurgery for rectal cancer: a prospective, single-blinded, randomized clinical trial. Surg Laparosc Endosc Percutan Tech 2015;25:399402.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Nascimbeni R, Burgart LJ, Nivatvongs S, et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002;45:200206.

  • 62.

    Yamamoto S, Watanabe M, Hasegawa H, et al. The risk of lymph node metastasis in T1 colorectal carcinoma. Hepatogastroenterology 2004;51:9981000.

  • 63.

    You YN, Baxter NN, Stewart A, et al. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg 2007;245:726733.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 64.

    van Oostendorp SE, Smits LJH, Vroom Y, et al. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment. Br J Surg 2020;107:17191730.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65.

    Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015;16:15371546.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Shaikh I, Askari A, Ourû S, et al. Oncological outcomes of local excision compared with radical surgery after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2015;30:1929.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Landmann RG, Wong WD, Hoepfl J, et al. Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum 2007;50:15201525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Kidane B, Chadi SA, Kanters S, et al. Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis. Dis Colon Rectum 2015;58:122140.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Nash GM, Weiser MR, Guillem JG, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009;52:577582.

  • 70.

    Stitzenberg KB, Sanoff HK, Penn DC, et al. Practice patterns and long-term survival for early-stage rectal cancer. J Clin Oncol 2013;31:42764282.

  • 71.

    Sajid MS, Farag S, Leung P, et al. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis 2014;16:214.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Lu JY, Lin GL, Qiu HZ, et al. Comparison of transanal endoscopic microsurgery and total mesorectal excision in the treatment of T1 rectal cancer: a meta-analysis. PLoS One 2015;10:e0141427.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg 1982;69:613616.

  • 74.

    Steup WH, Moriya Y, van de Velde CJ. Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Cancer 2002;38:911918.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Schlag PM. Surgical sphincter preservation in rectal cancer. Oncologist 1996;1:288292.

  • 76.

    Marr R, Birbeck K, Garvican J, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005;242:7482.

  • 77.

    Russell MM, Ganz PA, Lopa S, et al. Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. Ann Surg 2015;261:144148.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Huang A, Zhao H, Ling T, et al. Oncological superiority of extralevator abdominoperineal resection over conventional abdominoperineal resection: a meta-analysis. Int J Colorectal Dis 2014;29:321327.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Negoi I, Hostiuc S, Paun S, et al. Extralevator vs conventional abdominoperineal resection for rectal cancer-a systematic review and meta-analysis. Am J Surg 2016;212:511526.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Nagtegaal ID, van de Velde CJ, van der Worp E, et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002;20:17291734.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Parfitt JR, Driman DK. The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment. J Clin Pathol 2007;60:849855.

  • 82.

    Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006;8:800807.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 83.

    Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26:350357.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89:327334.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    den Dulk M, Putter H, Collette L, et al. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. Eur J Cancer 2009;45:11751183.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Påhlman L, Bohe M, Cedermark B, et al. The Swedish rectal cancer registry. Br J Surg 2007;94:12851292.

  • 87.

    Digennaro R, Tondo M, Cuccia F, et al. Coloanal anastomosis or abdominoperineal resection for very low rectal cancer: what will benefit, the surgeon’s pride or the patient’s quality of life? Int J Colorectal Dis 2013;28:949957.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 88.

    Pachler J, Wille-Jørgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev 2012;12:CD004323.

    • Search Google Scholar
    • Export Citation
  • 89.

    Bonjer HJ, Deijen CL, Abis GA, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 2015;372:13241332.

  • 90.

    Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol 2014;15:767774.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91.

    Fleshman J, Branda M, Sargent DJ, et al. Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA 2015;314:13461355.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Stevenson AR, Solomon MJ, Lumley JW, et al. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA 2015;314:13561363.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Lujan J, Valero G, Biondo S, et al. Laparoscopic versus open surgery for rectal cancer: results of a prospective multicentre analysis of 4,970 patients. Surg Endosc 2013;27:295302.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    van der Pas MH, Haglind E, Cuesta MA, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013;14:210218.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 2007;25:30613068.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Jayne DG, Thorpe H, Copeland J, et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 2010;97:16381645.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Kang SB, Park JW, Jeong SY, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 2010;11:637645.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 98.

    Wagman LD. Laparoscopic and open surgery for colorectal cancer: reaching equipoise? J Clin Oncol 2007;25:29962998.

  • 99.

    Fleshman J, Branda ME, Sargent DJ, et al. Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III rectal cancer: follow-up results of the ACOSOG Z6051 randomized controlled trial. Ann Surg 2019;269:589595.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Stevenson AR, Solomon MJ, Brown CSB, et al. Disease-free survival and local recurrence after laparoscopic-assisted resection or open resection for rectal cancer: the Australasian Laparoscopic Cancer of the Rectum randomized clinical trial. Ann Surg 2019;269:596602.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 101.

    Nussbaum DP, Speicher PJ, Ganapathi AM, et al. Laparoscopic versus open low anterior resection for rectal cancer: results from the national cancer data base. J Gastrointest Surg 2015;19:124131;discussion 131–132.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Araujo SE, da Silva eSousa AH Jr, de Campos FG, et al. Conventional approach x laparoscopic abdominoperineal resection for rectal cancer treatment after neoadjuvant chemoradiation: results of a prospective randomized trial. Rev Hosp Clin Fac Med Sao Paulo 2003;58:133140.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Gopall J, Shen XF, Cheng Y. Current status of laparoscopic total mesorectal excision. Am J Surg 2012;203:230241.

  • 104.

    Kuhry E, Schwenk WF, Gaupset R, et al. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008;2008:CD003432.

    • Search Google Scholar
    • Export Citation
  • 105.

    Lee JK, Delaney CP, Lipman JM. Current state of the art in laparoscopic colorectal surgery for cancer: update on the multi-centric international trials. Ann Surg Innov Res 2012;6:5.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Trastulli S, Cirocchi R, Listorti C, et al. Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. Colorectal Dis 2012;14:e277296.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Xiong B, Ma L, Zhang C. Laparoscopic versus open total mesorectal excision for middle and low rectal cancer: a meta-analysis of results of randomized controlled trials. J Laparoendosc Adv Surg Tech A 2012;22:674684.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Ahmad NZ, Racheva G, Elmusharaf H. A systematic review and meta-analysis of randomized and non-randomized studies comparing laparoscopic and open abdominoperineal resection for rectal cancer. Colorectal Dis 2013;15:269277.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Arezzo A, Passera R, Scozzari G, et al. Laparoscopy for rectal cancer reduces short-term mortality and morbidity: results of a systematic review and meta-analysis. Surg Endosc 2013;27:14851502.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Jiang JB, Jiang K, Dai Y, et al. Laparoscopic versus open surgery for mid-low rectal cancer: a systematic review and meta-analysis on short- and long-term outcomes. J Gastrointest Surg 2015;19:14971512.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 111.

    Morneau M, Boulanger J, Charlebois P, et al. Laparoscopic versus open surgery for the treatment of colorectal cancer: a literature review and recommendations from the Comité de l’évolution des pratiques en oncologie. Can J Surg 2013;56:297310.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 112.

    Ng SS, Lee JF, Yiu RY, et al. Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: a pooled analysis of 3 randomized controlled trials. Ann Surg 2014;259:139147.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 113.

    Vennix S, Pelzers L, Bouvy N, et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev 2014;2014:CD005200.

    • Search Google Scholar
    • Export Citation
  • 114.

    Zhang FW, Zhou ZY, Wang HL, et al. Laparoscopic versus open surgery for rectal cancer: a systematic review and meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 2014;15:99859996.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Zhao D, Li Y, Wang S, et al. Laparoscopic versus open surgery for rectal cancer: a meta-analysis of 3-year follow-up outcomes. Int J Colorectal Dis 2016;31:805811.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Martínez-Pérez A, Carra MC, Brunetti F, et al. Pathologic outcomes of laparoscopic vs open mesorectal excision for rectal cancer: a systematic review and meta-analysis. JAMA Surg 2017;152:e165665.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Huang YM, Huang YJ, Wei PL. Outcomes of robotic versus laparoscopic surgery for mid and low rectal cancer after neoadjuvant chemoradiation therapy and the effect of learning curve. Medicine (Baltimore) 2017;96:e8171.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 118.

    Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 2017;318:15691580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Kim MJ, Park SC, Park JW, et al. Robot-assisted versus laparoscopic surgery for rectal cancer: a phase II open label prospective randomized controlled trial. Ann Surg 2018;267:243251.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Li X, Wang T, Yao L, et al. The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer: a meta-analysis and systematic review. Medicine (Baltimore) 2017;96:e7585.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 121.

    Prete FP, Pezzolla A, Prete F, et al. Robotic versus laparoscopic minimally invasive surgery for rectal cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Surg 2018;267:10341046.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Miskovic D, Foster J, Agha A, et al. Standardization of laparoscopic total mesorectal excision for rectal cancer: a structured international expert consensus. Ann Surg 2015;261:716722.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Lai LL, Fuller CD, Kachnic LA, et al. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol 2006;33(Suppl 11):S7074.

  • 124.

    Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol 2005;23:61996206.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 125.

    Rahbari NN, Elbers H, Askoxylakis V, et al. Neoadjuvant radiotherapy for rectal cancer: meta-analysis of randomized controlled trials. Ann Surg Oncol 2013;20:41694182.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:17851796.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 127.

    Tepper JE, O’Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol 2002;20:17441750.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Guillem JG, Díaz-González JA, Minsky BD, et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008;26:368373.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 129.

    Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 2014;12:513519.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668674.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: grupo cancer de recto 3 study. J Clin Oncol 2010;28:859865.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Perez K, Safran H, Sikov W, et al. Complete neoadjuvant treatment of rectal cancer: the Brown University Oncology Group CONTRE study. Am J Clin Oncol 2017;40:283287.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 133.

    Maréchal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012;23:15251530.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011;16:614620.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 2015;26:17221728.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Sclafani F, Brown G, Cunningham D, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol 2016;27:15571565.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015;16:957966.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:2942.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021;22:702715.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg 2020;271:440448.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Kasi A, Abbasi S, Handa S, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open 2020;3:e2030097.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018;4:e180071.

  • 143.

    Smith JJ, Chow OS, Gollub MJ, et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 2015;15:767.

    • Search Google Scholar
    • Export Citation
  • 144.

    Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022;40:25462556.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 2019;37:32123222.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 146.

    Fokas E, Schlenska-Lange A, Polat B, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol 2022;8:e215445.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Zhang J, Huang M, Cai Y, et al. Neoadjuvant chemotherapy with mFOLFOXIRI without routine use of radiotherapy for locally advanced rectal cancer. Clin Colorectal Cancer 2019;18:238244.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Masi G, Vivaldi C, Fornaro L, et al. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Eur J Cancer 2019;110:3241.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:17311740.

  • 150.

    Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:19261933.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 151.

    Wagman R, Minsky BD, Cohen AM, et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998;42:5157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Bujko K, Kepka L, Michalski W, et al. Does rectal cancer shrinkage induced by preoperative radio(chemo)therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 2006;80:412.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Wong RK, Tandan V, De Silva S, et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007;2:CD002102.

    • Search Google Scholar
    • Export Citation
  • 154.

    Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:46204625.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 155.

    Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol 2005;23:56205627.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:11141123.

  • 157.

    Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009;1:CD006041.

    • Search Google Scholar
    • Export Citation
  • 158.

    McCarthy K, Pearson K, Fulton R, et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012;12:CD008368.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    De Caluwé L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2013;2:CD006041.

    • Search Google Scholar
    • Export Citation
  • 160.

    Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006;24:35423547.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    O’Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502507.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579588.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 163.

    O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014;32:19271934.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst 2015;107:djv248.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 165.

    Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:27732780.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    Gérard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012;30:45584565.

  • 167.

    Azria D, Doyen J, Jarlier M, et al. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol 2017;28:24362442.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Schmoll HJ, Stein A, Van Cutsem E, et al. Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol 2021;39:1729.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 169.

    Rödel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015;16:979989.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 170.

    Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012;13:679687.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 171.

    Glynne-Jones R. Rectal cancer--the times they are a-changing. Lancet Oncol 2012;13:651653.

  • 172.

    Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol 2016;34:33003307.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 173.

    Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol 2019;37:32233233.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Feng YR, Zhu Y, Liu LY, et al. Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial. Oncotarget 2016;7:2557625584.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012;30:16201627.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 176.

    Eisterer W, De Vries A, Öfner D, et al. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. Anticancer Res 2014;34:67676773.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Kripp M, Horisberger K, Mai S, et al. Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer? Long-term results from phase II trials. Gastroenterol Res Pract 2015;2015:273489.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Helbling D, Bodoky G, Gautschi O, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2013;24:718725.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Pinto C, Di Bisceglie M, Di Fabio F, et al. Phase II study of preoperative treatment with external radiotherapy plus panitumumab in low-risk, locally advanced rectal cancer (RaP Study/STAR-03). Oncologist 2018;23:912918.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Landry JC, Feng Y, Prabhu RS, et al. Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN Cancer Research Group E3204. Oncologist 2015;20:615616.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Borg C, Mantion G, Boudghène F, et al. Efficacy and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: final results of a randomized, noncomparative phase 2 INOVA study. Clin Colorectal Cancer 2019;18:200208.e1.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 182.

    Maeda K, Shibutani M, Otani H, et al. Neoadjuvant radiotherapy with capecitabine plus bevacizumab for locally advanced lower rectal cancer: results of a single-institute phase II study. Anticancer Res 2018;38:41934197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 183.

    Spigel DR, Bendell JC, McCleod M, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer 2012;11:4552.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 184.

    Fernández-Martos C, Pericay C, Losa F, et al. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol 2019;5:15661573.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Bendell JC, Thompson D, Hemphill BM, et al. A phase 2 study of 5-fluorouracil (5-FU), ziv-aflibercept, and radiation for the preoperative and adjuvant treatment of patients with stage II/III rectal cancer. Cancer Invest 2017;35:535540.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014;32:513518.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 187.

    Hasegawa S, Goto S, Matsumoto T, et al. A multicenter phase 2 study on the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Ann Surg Oncol 2017;24:35873595.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 188.

    Jalil O, Claydon L, Arulampalam T. Review of neoadjuvant chemotherapy alone in locally advanced rectal cancer. J Gastrointest Cancer 2015;46:219236.

  • 189.

    Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:23632376.

  • 190.

    Gay HA, Barthold HJ, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys 2012;83:e353362.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Bae BK, Kang MK, Kim JC, et al. Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. Radiat Oncol J 2017;35:208216.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 192.

    Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys 2008;71:11811188.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 194.

    Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279286.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 195.

    Petrelli F, Sgroi G, Sarti E, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 2016;263:458464.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 196.

    Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 2013;100:933939.

  • 197.

    Tulchinsky H, Shmueli E, Figer A, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:26612667.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Probst CP, Becerra AZ, Aquina CT, et al. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg 2015;221:430440.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 199.

    Huntington CR, Boselli D, Symanowski J, et al. Optimal timing of surgical resection after radiation in locally advanced rectal adenocarcinoma: an analysis of the National Cancer Database. Ann Surg Oncol 2016;23:877887.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 200.

    Sun Z, Adam MA, Kim J, et al. Optimal timing to surgery after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Am Coll Surg 2016;222:367374.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 201.

    Gambacorta MA, Masciocchi C, Chiloiro G, et al. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother Oncol 2021;154:154160.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Lefevre JH, Mineur L, Kotti S, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 2016;34:37733780.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 203.

    Lefèvre JH, Mineur L, Cachanado M, et al. Does a longer waiting period after neoadjuvant radio-chemotherapy improve the oncological prognosis of rectal cancer?: three years’ follow-up results of the Greccar-6 randomized multicenter trial. Ann Surg 2019;270:747754.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 204.

    Cedermark B, Dahlberg M, Glimelius B, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980987.

  • 205.

    Birgisson H, Påhlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005;23:86978705.

    • Crossref
    • PubMed